Marinus Pharmaceuticals. has filed a patent for an injectable ganaxolone formulation containing ganaxolone, sulfobutyl ether-ß-cyclodextrin, and water. The formulation can be used to treat seizure disorders, strokes, and traumatic brain injuries. Additional active agents can be combined for enhanced treatment. GlobalData’s report on Marinus Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Marinus Pharmaceuticals Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Marinus Pharmaceuticals, Nanoparticle drug conjugates was a key innovation area identified from patents. Marinus Pharmaceuticals's grant share as of January 2024 was 26%. Grant share is based on the ratio of number of grants to total number of patents.

Injectable ganaxolone formulation for treating seizure disorders

Source: United States Patent and Trademark Office (USPTO). Credit: Marinus Pharmaceuticals Inc

The patent application (Publication Number: US20240016817A1) discloses an aqueous injectable ganaxolone formulation. The formulation includes ganaxolone at a concentration of about 1 mg/ml, sulfobutyl ether-ß-cyclodextrin, and a buffer selected from either a phosphate or citrate buffer. The ganaxolone and sulfobutyl ether-ß-cyclodextrin form an inclusion complex, with a weight-to-weight ratio of about 52:1 to 70:1. The pH of the aqueous injectable formulation ranges from about 6.01 to 7.10.

Furthermore, the formulation may be designed for intravenous administration and may include a tonicity adjusting agent, such as sodium chloride, to ensure isotonicity with human plasma. The formulation may be contained within a glass vial and utilize a citrate or phosphate buffer. These specific details outlined in the claims provide a clear and detailed description of the aqueous injectable ganaxolone formulation, highlighting the key components and ratios required for its preparation and administration.

To know more about GlobalData’s detailed insights on Marinus Pharmaceuticals, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies